.png "back to home page")
https://t.co/OohaOrWy7C
— 地震星 (@a3pCEcbCvlM0kHc) October 16, 2020
レムデシビルは使えない奴だったみたいな話
CNN
「これまで、レムデシビルはコロナウイルスに特定の効果があると思われる唯一の薬でした。これは、米国食品医薬品局からCovid-19の緊急使用許可を得た唯一の薬剤でした。」とあるぞ・・・
Sigh....and America just bought up almost the ENTIRE GLOBAL STOCK of it! ?♂️https://t.co/ST9kv53GWM
— Scott Nevins (@ScottNevins) October 16, 2020
I'm disappointed with the #remdesivir results and no clear survival benefit. But what also saddens me is the seemingly "gleeful" articulation of the results as if there's some sort of politically-based satisfaction. It really sucks. https://t.co/cMTn3OWcrj #COVID19
— John Nosta (@JohnNosta) October 16, 2020
Remdesivir is one of two therapeutics with FDA EUA approval, the other is convalescent plasma. I've yet to see any data for either treatment that would suggest they are effective. The world is ready for $RLFTF.
— Harvey Speculator (@HarveySpecTrade) October 16, 2020
-Effective
-Cheap to produce
-Proven Safehttps://t.co/oZl7L8FVJW
The interim results of the WHO's study indicated that remdesivir, along with three other drugs, “appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.” @CNBCi #coronavirus https://t.co/CPSMmiZVaf
— Vicky McKeever (@VMcKeeverCNBC) October 16, 2020
Remdesivir - and 3 other drugs - all failed to reduce #COVID19 deaths or hospitalization in a WHO study.
— Global Health Strategies (@GHS) October 16, 2020
So a great deal is resting on the potential efficacy & safety of monoclonal antibodies developed by Regeneron and Eli Lilly that are now in Phase 3. https://t.co/FoRV0C9Dn0
An antiviral [#remdesivir] widely used to treat hospitalized patients did not lower the mortality rate in a multinational trial.https://t.co/O6PEJ6StJ4
— The HighWire (@HighWireTalk) October 16, 2020
All I have to say about this: https://t.co/At7D8qq3Hv
— Esther Choo, MD MPH (@choo_ek) October 16, 2020
Is this: https://t.co/lkr7vXrWGI
Guess what? No prevention of death from Covid-19, says study of 11,000 patients worldwide of Trumpy’s second favorite drug Remdesivir (he owned stock in its manufacturer, as well as in Regeneron) https://t.co/BvS31SQoCJ
— Keith Olbermann (@KeithOlbermann) October 16, 2020
“The study’s authors called the findings “unpromising” and said they “suffice to refute early hopes” that [remdesivir] “will substantially reduce inpatient mortality, initiation of ventilation or hospitalization duration.” Sigh. This in 11,000 patients. ☹️ https://t.co/hSjUk2pgWS
— Mikkael Sekeres MD (@MikkaelSekeres) October 16, 2020
I spoke to @KatherineJWu to put the Solidarity trial results into focus
— Ilan Schwartz MD PhD (@GermHunterMD) October 16, 2020
“This puts the issue to rest — there is certainly no mortality benefit”https://t.co/kHHFgP9wpk
can literally anyone be surprised by this?
— el gato malo (@boriquagato) October 16, 2020
we knew this all along.
this is why the NIH allowed gilead to change the primary endpoint of this trial 2 weeks before it read out: because it provided no survival benefit and they could see it in the data.https://t.co/vk4br7qIJR
Many of us are ??♀️about the news that remdesivir may not, actually, change mortality for #COVID19.
— Megan Ranney MD MPH ? (@meganranney) October 16, 2020
Why?https://t.co/MYW7QDY9A3 @KatherineJWu @ginakolata
#remdesivir, the only antiviral drug authorized for treatment of #COVID19 in the US, fails to prevent deaths among patients, according to a study of >11,000 people in 30 countries sponsored by @WHO.https://t.co/3R2KX717xU #coronavirus
— MicrobesInfect (@MicrobesInfect) October 16, 2020
?... really? Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial - The New York Times https://t.co/pWKuFw7VvG
— Corey?Reynolds (@coreyreynoldsLA) October 16, 2020
Months ago, Fauci announced #remdesivir as the "standard of care" for #COVID19, despite lack of mortality benefit in studies.
— Steven Phillips, MD (@StevePhillipsMD) October 16, 2020
Now, multi-national study of11,000 people: No mortality benefit, but remdesivir is still FDA approved for COVID19?https://t.co/g0fJI3NTmM
Massive WHO remdesivir study suggests no Covid-19 benefit. Doctors aren't so sure. https://t.co/A6vuUvUbDW
— Roger Paredes (@RutgerWalls) October 17, 2020
Massive WHO remdesivir study suggests no Covid-19 benefit. Doctors aren't so sure. https://t.co/JKea2M9oHI via @nbcnews @KLynQ @camwolfe
— Erika Edwards (@erikaedwardsnbc) October 16, 2020
Massive WHO remdesivir study suggests no Covid-19 benefit. Doctors aren't so sure. https://t.co/kOSDZ1RJ0Z via @erikaedwardsnbc
— Evan Rosenfeld (@Evan_Rosenfeld) October 16, 2020
4 coronavirus treatments, including remdesivir, hydroxychloroquine, flop in large WHO study. Look at #leronlimab#FDAhttps://t.co/sXduSNDeYr
— Joshua (@erjo06026) October 16, 2020